Organon & Co. (OGN) News
Filter OGN News Items
OGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OGN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OGN News From Around the Web
Below are the latest news stories about ORGANON & CO that investors may wish to consider to help them evaluate OGN as an investment opportunity.
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)Organon & Co. (OGN) JPMorgan Annual Healthcare Conference Call January 13, 2025, 06:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Presentation Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team. From the company, we have CEO, Kevin Ali as well as CFO, Matt Walsh. Kevin and Matt, Happy New Year. Thanks for joining us. Kevin Ali Happy New Year. Chris Schott And looking forward to the... |
Organon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJERSEY CITY, N.J., December 19, 2024--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th |
FDA approves Organon’s VTAMA cream, 1% for the treatment for ADOrganon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis AD in adults and pediatric patients 2 years of age and older.Organon received the FDA approval prior to its extended target action date PDUFA of March 12. “With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there |
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderJERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older. |
Organon's (NYSE:OGN) Earnings Are Weaker Than They SeemDespite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found some... |
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their ForecastsOrganon & Co. ( NYSE:OGN ) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to... |
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderJERSEY CITY, N.J., November 05, 2024--The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed. |
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 12th of December. Based on... |
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)Organon ( NYSE:OGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.58b (up 4.1% from 3Q 2023). Net... |
Organon Reports Results for the Third Quarter Ended September 30, 2024JERSEY CITY, N.J., October 31, 2024--Organon Reports Q3 2024 Earnings |